Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Do institutionals & insiders believe in SNY or NVO?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is SNY or NVO a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.4%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has better valuation & earnings, SNY or NVO?

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.46B	2.68	$6.02B	$2.80	17.36
Novo Nordisk A/S	$42.12B	7.31	$14.64B	$3.38	20.39

Do analysts rate SNY or NVO?

Sanofi presently has a consensus target price of $61.50, suggesting a potential upside of 26.52%. Novo Nordisk A/S has a consensus target price of $112.00, suggesting a potential upside of 62.48%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

Does the media favor SNY or NVO?

In the previous week, Sanofi had 4 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 46 mentions for Sanofi and 42 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 1.16 beat Sanofi's score of 0.84 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	18 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	33 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	14.56%	17.15%	9.80%
Novo Nordisk A/S	34.52%	80.94%	24.23%

Which has more volatility & risk, SNY or NVO?

Sanofi has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.